Rob Ree is the founder of NorthSea Therapeutics. NorthSea Therapeutics has raised $40M in total funding. Latest round: Series B.
Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of Dezima Pharma, which was acquired by Amgen in 2015, and as the CEO of BMEYE, acquired by Edwards Lifesciences in 2012. He also served as the head of licensing at Crucell and held various sales and marketing roles at Medtronic. He holds a PharmD from the University of Groningen.
Full founder directory · Investor directory · Company funding database · Fundraising library